Drugs / MSJ-0011
MSJ-0011
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01653743 | Sep 2012 → Nov 2014 | anovulation, hypothalamic dysfunction, polycystic ovary syndrome | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSJ-0011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01653743 ↗ |
| Known as | choriogonadotropin alfa | “will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa [recombinant human Chorionic Gonadotropin, r-hCG]) subcutaneously (SC)” NCT01653743 ↗ |
| Known as | r-hCG | “will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa [recombinant human Chorionic Gonadotropin, r-hCG]) subcutaneously (SC)” NCT01653743 ↗ |
| Known as | recombinant human Chorionic Gonadotropin | “will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa [recombinant human Chorionic Gonadotropin, r-hCG]) subcutaneously (SC)” NCT01653743 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human Chorionic Gonadotropin” NCT01653743 ↗ |
| Route | Subcutaneous | “subcutaneously (SC)” NCT01653743 ↗ |